Cohort of Liver Transplant Patients with Hepatitis C Recurrence Treated with Direct Acting Antiviral Agent

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"– elderly subjects over 18 years old – transplanted liver – infected with HCV before transplantation – presenting Hepatitis C virus (HCV) infection recurrence (regardless of genotype) with detectable HCV RNA at baseline – received or receiving antiviral therapy with a direct antiviral agent or having completed treatment but still being monitored (within 48 weeks after completing treatment) – member of a social security scheme – signed consent form N.B.: Included – multiple transplants – treatment-naive or failed treatment patients, before and after transplantation, regardless of previous model – patients with HIV or HBV co-infection – all stages of hepatic fibrosis","clusion_E":""}